384 related articles for article (PubMed ID: 29496043)
1. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
[TBL] [Abstract][Full Text] [Related]
3. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
[TBL] [Abstract][Full Text] [Related]
4. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma.
Zenga J; Wilson M; Adkins DR; Gay HA; Haughey BH; Kallogjeri D; Michel LS; Paniello RC; Rich JT; Thorstad WL; Nussenbaum B
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1118-27. PubMed ID: 25902372
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation.
Guo TW; Saiyed F; Yao CMKL; Kiong KL; Martinez J; Sacks R; Lee JJ; Moreno AC; Frank SJ; Rosenthal DI; Glisson BS; Ferrarotto R; Mott FE; Johnson FM; Myers JN
Cancer; 2021 Aug; 127(16):2916-2925. PubMed ID: 33873251
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by concurrent chemoradiotherapy for advanced stage oropharyngeal squamous cell carcinoma with HPV and P16 testing.
Flavill E; Fang YV; Miles B; Truelson J; Perkins S
Ann Otol Rhinol Laryngol; 2014 May; 123(5):365-73. PubMed ID: 24687594
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.
Yoon DH; Cho Y; Kim SY; Nam SY; Choi SH; Roh JL; Lee SW; Song SY; Lee JH; Kim JS; Cho KJ; Kim SB
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):118-25. PubMed ID: 20675065
[TBL] [Abstract][Full Text] [Related]
10. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
12. Enhancing regional control in p16-negative oropharyngeal cancer: A propensity score-matched analysis of upfront neck dissection and definitive chemoradiotherapy.
Lee TL; Fang WC; Lee IC; Lirng JF; Chang CF; Hsu YB; Chu PY; Wang YF; Yang MH; Chang PM; Wang LW; Tai SK
J Chin Med Assoc; 2024 May; 87(5):516-524. PubMed ID: 38501795
[TBL] [Abstract][Full Text] [Related]
13. Prediction of concurrent chemoradiotherapy outcome in advanced oropharyngeal cancer.
Hasegawa M; Maeda H; Deng Z; Kiyuna A; Ganaha A; Yamashita Y; Matayoshi S; Agena S; Toita T; Uehara T; Suzuki M
Int J Oncol; 2014 Sep; 45(3):1017-26. PubMed ID: 24969413
[TBL] [Abstract][Full Text] [Related]
14. The role of concomitant chemoradiotherapy in AJCC 7
Lu DJ; Luu M; Nguyen AT; Shiao SL; Scher K; Mita A; Anderson E; Clair JM; Ho AS; Zumsteg ZS
Oral Oncol; 2020 Nov; 110():104882. PubMed ID: 32650257
[TBL] [Abstract][Full Text] [Related]
15. Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer.
Iganej S; Beard BW; Chen J; Buchschacher GL; Abdalla IA; Thompson LDR; Bhattasali O
Oral Oncol; 2019 Oct; 97():18-22. PubMed ID: 31421466
[TBL] [Abstract][Full Text] [Related]
16. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zumsteg ZS; Lok BH; Ho AS; Drill E; Zhang Z; Riaz N; Shiao SL; Ma J; McBride SM; Tsai CJ; Baxi SS; Sherman EJ; Lee NY
Cancer; 2017 Apr; 123(8):1345-1353. PubMed ID: 27984656
[TBL] [Abstract][Full Text] [Related]
17. A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx.
Huang PW; Lin CY; Hsieh CH; Hsu CL; Fan KH; Huang SF; Liao CT; Ng SK; Yen TC; Chang JT; Wang HM
Biomed J; 2018 Apr; 41(2):129-136. PubMed ID: 29866601
[TBL] [Abstract][Full Text] [Related]
18. Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan.
Saito Y; Hayashi R; Iida Y; Mizumachi T; Fujii T; Matsumoto F; Beppu T; Yoshida M; Shinomiya H; Kamiyama R; Kitano M; Yokoshima K; Fujimoto Y; Hama T; Yamashita T; Okami K; Miura K; Fujisawa T; Sano D; Kato H; Minami S; Sugasawa M; Masuda M; Ota I; Iwae S; Kawata R; Monden N; Imai T; Asakage T; Okada M; Yoshikawa T; Tanioka K; Kitayama M; Doi M; Fujii S; Fujii M; Oridate N; Nakamizo M; Yoshimoto S; Homma A; Nibu KI; Yane K
Cancer; 2020 Sep; 126(18):4177-4187. PubMed ID: 32648953
[TBL] [Abstract][Full Text] [Related]
19. Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning.
Chen TM; Chen WM; Chen M; Shia BC; Wu SY
J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):14. PubMed ID: 36782296
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
